Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 17.40
-0.64 (-3.55%)
May 12, 2026, 3:12 PM CST
SHE:300497 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | -4.01 | -62.97 | -272.1 | -200.8 | -141.47 | 48.83 |
Depreciation & Amortization | 187.56 | 187.56 | 170.72 | 159.46 | 123.84 | 98.57 |
Other Amortization | - | - | 0.37 | - | - | 1.13 |
Loss (Gain) From Sale of Assets | 0.38 | 0.38 | 0.1 | -0.08 | -0.41 | 0.06 |
Asset Writedown & Restructuring Costs | 15.06 | 15.06 | 101.63 | 24.88 | 13.89 | 5.93 |
Loss (Gain) From Sale of Investments | 12.56 | 12.56 | 15.52 | 16.19 | 1.44 | 47.94 |
Provision & Write-off of Bad Debts | - | - | -0.87 | 0.91 | 0.79 | - |
Other Operating Activities | -30.7 | 48.24 | 85.6 | 49 | 178.9 | 96.84 |
Change in Accounts Receivable | -16.76 | -16.76 | 13.09 | -159.45 | -273.95 | -199.39 |
Change in Inventory | 33.71 | 33.71 | -44.8 | 74.55 | -259.58 | -154.85 |
Change in Accounts Payable | -152.61 | -152.61 | 128.91 | -33.38 | 232.27 | 139.1 |
Change in Other Net Operating Assets | - | - | - | 7.03 | 1.66 | 6.32 |
Operating Cash Flow | 42.7 | 62.67 | 187.64 | -64.76 | -120.85 | 72.32 |
Operating Cash Flow Growth | -71.85% | -66.60% | - | - | - | -81.08% |
Capital Expenditures | -149.37 | -224.88 | -141.75 | -242.23 | -459.41 | -679.6 |
Sale of Property, Plant & Equipment | 2.15 | 0.74 | 1.1 | 1.61 | 3.81 | 0.3 |
Investment in Securities | 63.23 | 3.09 | - | -114.72 | -53.6 | -73.25 |
Other Investing Activities | 1.06 | 1.17 | 1.04 | 0.83 | 0.87 | 17.06 |
Investing Cash Flow | -82.93 | -219.88 | -139.61 | -354.5 | -508.34 | -735.48 |
Long-Term Debt Issued | - | 950 | 641 | 956.44 | 1,241 | 1,048 |
Long-Term Debt Repaid | - | -903.78 | -658.78 | -729.98 | -830.49 | -488.5 |
Net Debt Issued (Repaid) | -48.58 | 46.22 | -17.78 | 226.47 | 410.51 | 559.11 |
Issuance of Common Stock | - | - | - | - | - | 34.79 |
Repurchase of Common Stock | - | - | -18 | - | -69.75 | -105.11 |
Common Dividends Paid | -54.5 | -54.77 | -55.5 | -55.79 | -54.58 | -139.18 |
Other Financing Activities | 44.07 | 81.16 | 3.5 | -20.91 | -3.2 | - |
Financing Cash Flow | -59.01 | 72.62 | -87.78 | 149.76 | 282.99 | 349.61 |
Foreign Exchange Rate Adjustments | -2.68 | -0.18 | 7.83 | 3 | 9.51 | 0.74 |
Net Cash Flow | -101.93 | -84.76 | -31.92 | -266.5 | -336.69 | -312.81 |
Free Cash Flow | -106.67 | -162.21 | 45.89 | -306.99 | -580.26 | -607.28 |
Free Cash Flow Margin | -8.15% | -13.69% | 3.90% | -19.07% | -35.23% | -42.48% |
Free Cash Flow Per Share | -0.20 | -0.29 | 0.09 | -0.57 | -1.07 | -1.12 |
Cash Income Tax Paid | 17.41 | 12.78 | -98.69 | -15.84 | -54.01 | 19.34 |
Levered Free Cash Flow | -144.32 | -273.81 | 66.66 | -379.88 | -536.77 | -490.78 |
Unlevered Free Cash Flow | -144.29 | -273.81 | 92.02 | -353.61 | -511.08 | -475.2 |
Change in Working Capital | -138.15 | -138.15 | 89.04 | -115.96 | -300.32 | -226.98 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.